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East Coast fever (ECF), caused by Theileria parva, is the most important tick-borne disease of cattle in sub-Saharan Africa.
Practical disadvantages associated with the currently used live-parasite vaccine could be overcome by subunit vaccines. An 80-aa
polypeptide derived from the C-terminal portion of p67, a sporozoite surface Ag and target of neutralizing Abs, was the focus of
the efforts on subunit vaccines against ECF and subjected to several vaccine trials with very promising results. However, the
vaccination regimen was far from optimized, involving three inoculations of 450 mg of soluble p67C (s-p67C) Ag formulated in the
Seppic adjuvant Montanide ISA 206 VG. Hence, an improved formulation of this polypeptide Ag is needed. In this study, we
report on two nanotechnologies that enhance the bovine immune responses to p67C. Individually, HBcAg-p67C (chimeric hep-
atitis B core Ag virus-like particles displaying p67C) and silica vesicle (SV)–p67C (s-p67C adsorbed to SV-140-C18, octadecyl-
modified SVs) adjuvanted with ISA 206 VG primed strong Ab and T cell responses to p67C in cattle, respectively. Coimmunization
of cattle (Bos taurus) with HBcAg-p67C and SV-p67C resulted in stimulation of both high Ab titers and CD4 T cell response to
p67C, leading to the highest subunit vaccine efficacy we have achieved to date with the p67C immunogen. These results offer the
much-needed research depth on the innovative platforms for developing effective novel protein-based bovine vaccines to further
the advancement. The Journal of Immunology, 2021, 206: 000–000.
E
ast Coast fever (ECF) is a lethal disease of cattle affecting
12 countries in sub-Saharan Africa. The disease, caused by
a tick-transmitted apicomplexan organism called Theileria
parva, represents a significant constraint to increasing livestock
productivity in smallholder and pastoral farming systems (1).
A virulent, live sporozoite vaccine based on an “infection and
treatment method,” referred to as “ITM,” is commercially avail-
able but it is difficult to manufacture, it requires oversight and
expertise for its use, and it is expensive (2). Hence, several lab-
oratories are working toward development of ECF subunit vac-
cines. Although a classical CTL response to schizont-infected
cells plays a major role in mediating immunity to ECF (3–5), we
and others have previously demonstrated that immune responses
to p67, the major surface stage–specific Ag of sporozoites, can
contribute to protective immunity (6, 7).
Full-length recombinant p67 protein and fragments of it have
been the subject of several experimental vaccine trials (reviewed in
Ref. 8). Current efforts are focused on an 80-aa polypeptide se-
quence from the C-terminal end of p67, referred to as p67C. It
contains two nonoverlapping epitopes recognized by murine
sporozoite-neutralizing mAbs (9). Remarkably, an immunization
regimen involving three inoculations of 450 mg of soluble p67C
(s-p67C) Ag formulated in the Seppic adjuvant Montanide ISA
206 VG primes immunity to ECF in ∼50% of vaccinated cattle
against an LD70 sporozoite challenge (7), an efficacy level that is
equivalent to that primed by p67 (7, 10). However, reducing the
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number of inoculations of p67C to two resulted in immunity to
ECF in only ∼25% of vaccinated cattle (11). Hence, an improved
formulation of this polypeptide Ag is needed. With this objective
in mind, we have explored improving the immune responses to
p67C by changing its presentation to the bovine immune system
from a monomeric soluble Ag to a particulate multimeric one by
using two nanoparticle platform technologies.
The first platform exploits the ability of the core Ag of hepatitis B
virus (HBcAg) to fold into chimeric icosahedral-shaped virus-like
particles (VLPs) following insertion of heterologous Ag sequences
into the domain between aa 76 and 81 of HBcAg. This results in the
display of foreign Ags at the top of a spike structure called the
major immunodominant region at the surface of the VLP in a
regular array that can translate into superior stimulation of Ag-
specific Ab responses (12). Exploitation of this system as a ge-
neric Ag delivery system has, however, been hampered by finding
that HBcAg generally permits insertion of short polypeptide se-
quences (#100 residues) as longer sequences often disrupt di-
merization of HBcAg monomers and subsequent VLP formation
(12–15). Chimeric VLPs have been used to improve the immune
response to defined Ags, like SR1 from Theileria annulata (14)
or VP1 capsid protein from foot-and-mouth disease virus (15),
among others.
The second nanoparticle platform exploits the capacity of
spherical hollow silica vesicles (SVs) to adsorb a range of different
types and sizes of molecules onto their external and internal sur-
faces via electrostatic interactions (16). SVs have not been ex-
tensively tested as an Ag delivery system because of a lack of
uniformity in their synthesis. However, a robust, simple two-step
fabrication process of SVs that controls vesicle wall thickness,
diameter, and pore size was recently described. The SV surfaces
can be functionally modified by amino or hydrophobic groups to
empirically optimize the adsorption of Ags (17). SVs with a di-
ameter of 50 nm are of an ideal size for endocytosis and they have
been shown to adsorb whole Ags and to enhance the immuno-
genicity of Anaplasma marginale Ags in mice (18) and of the E2
Ag of bovine viral diarrhea virus 1 (BVDV-1) in sheep (19).
In this study, we report on the immunogenicity of p67C fol-
lowing immunization of cattle with s-p67C, chimeric HBcAg VLPs
displaying p67C (HBcAg-p67C), s-p67C adsorbed to SV-140-C18
SVs (SV-p67C), and a combination of SV-p67C and HBcAg-
p67C. All Ags were formulated with the adjuvant ISA 206 VG.
In these comparative studies, HBcAg-p67C induced the highest
level of p67C Ab responses and a switch in Ab subtype but a poor
CD4+ T cell response, and SV-p67C induced a strong CD4+ T cell
response but lower levels of Abs. Immunization with a combi-
nation of SV-p67C and HBcAg-p67C induced high p67C-specific
Ab and CD4+ T cell responses and resulted in the highest levels of
protection to T. parva sporozoite challenge.
Materials and Methods
Bacterial-derived s-p67C, HBcAg-p67C, and control HBcAg
VLP production and characterization
To generate s-p67C, residues 572–651 of T. parva (Muguga) p67 Ag were
cloned as a BamHI-HindIII fragment in pET-28a+ (Novagen). The total
length of the p67C fusion protein is 114 aa residues of which the terminal 80
residues encode p67C (10) (Table I). Bulk production and purification of
100 mg s-p67C was out-sourced to GenScript Biotech. Briefly, Escherichia
coli pellets were lysed by sonication in guanidine hydrochloride and the
target protein obtained by one-step purification using an Ni-affinity column
under denaturing conditions. Fractions were pooled, extensively dialyzed
against PBS followed by 0.22 mm filter sterilization, and stored at280˚C. As
judged by SDS-PAGE, the protein was .95% pure.
To generate HBcAg-p67C, p67C cDNA was amplified from T. parva
Muguga sporozoite first-strand cDNA prepared using the Omniscript Re-
verse Transcription Kit (Qiagen). Gene-specific primers (p67C forward:
59-CCCCgttaacTTGGAAGATGGTGGTGGTGGTTCTGGTGGTGGT-
GGTGGAACGGGAGGGGGATCA-39; and p67C reverse: 59-CCAC-
AATAGCAGCTGGAGGAGAAGGTGGTGGTGGTTCTGGTGGTGGTG-
GTCCAgctagcCCC-39) contained a 9-aa linker [(G)4S(G)4, underlined] and
restriction enzyme sites for HpaI or NheI (lowercase) to allow directional
cloning of the PCR product first into the pGEM-T easy vector (Promega)
and then into pBAD/B-HBcAg (20). Integration of p67C occurs between
aa 78 and 79 of HBcAg (Table I). All clones were sequence verified and
the three-dimensional structure of the HBcAg-p67C fusion protein was
predicted by using the protein structure homology modeling server
SWISS-MODEL (21).
HBcAg-p67C and HBcAg protein expression, purification, and forma-
tion of VLPs was as previously described (22). These experiments were
performed at the Integrated Molecular Plant Physiology Research group of
the University of Antwerp. Briefly, a single E. coli MC1061 colony con-
taining pBAD/B-HBcAg-p67C was grown overnight in 5 ml of Luria-
Bertani (Sigma-Aldrich) broth and used to seed larger cultures before
addition of L-arabinose (0.02% w/v; Sigma-Aldrich) for the induction of
HBcAg-p67C fusion protein expression. Cells were lysed using a French
cell press (10,000 p.s.i.; SLM Aminco), the clarified supernatant was
loaded on a 10-ml DEAE Sephacel column (GE Healthcare), and the flow
through was collected (25 ml). Following two rounds of ammonium sulfate
precipitations, first at 20% and then at 15%, the final pellet was solubilized
in 2 ml of wash buffer (50 mM Tris/HCl, 100 mM NaCl, 0.01% Triton-
X100, pH8) and dialyzed overnight using 5 l of wash buffer to allow
protein refolding and VLP formation. After centrifugation, the supernatant
was loaded on a gel filtration column (height: 100 cm, diameter 2.5 cm
Sephacryl S-300; GE Healthcare) and protein fractions in the void volume
were collected. Control HBcAg VLPs were obtained using the pBAD/B-
HBcAg vector, following the same procedure.
Purified proteins were separated by SDS-PAGE, and gels were stained
with a Colloidal Blue Staining Kit (Invitrogen) or Coomassie Brilliant Blue
(Sigma-Aldrich) and were also analyzed by Western blot with anti-p67C
mAb ARIV 21.4 (9) (ascites diluted at 1/1000) and secondary anti-
mouse–HRP Ab (Sigma-Aldrich). Protein quantities were measured by a
BCA Protein Assay Kit (Pierce) and evaluation of the particle formation
was done using electron microscopy on a 2010 Tecnai G2 (FEI) trans-
mission electron microscope. Samples were coated on Formvar/Carbon
support film grids (no. FCF200CU; Laboprimex) and negatively stained
with 1% phosphotungstic acid (pH 8).
Identification of different SVs capacity to adsorb s-p67C
A range of different SVs (SV-50, SV-50–NH2, SV-50–C18, SV-100, SV-
100–NH2, SV-140, SV-140–NH2, and SV-140–C18 particles [Table II])
were generated as previously described (23) and were incubated with
s-p67C in sterile PBS (Life Technologies). The particle-protein slurry was
incubated overnight on a shaker at 200 rpm at 4˚C followed by SDS-PAGE
analysis of the SVs and supernatant fractions. The relative abundance of
Ag adsorbed was ranked arbitrarily depending on the amount of Ag on the
supernatants after centrifugation. This led to identification of SV-140–C18
SVs as having the highest capacity for adsorption of s-p67C. By varying
the ratio of SV to s-p67C, 1 mg of SV-140–C18 was found to adsorb 133 mg
of s-p67C.
Synthesis and characterization of SV-140–C18 SVs
The two-step production of SVs has been previously described (17). Briefly,
in step one, 0.5 g of EO39BO47EO39 [commercial name B50–6600, EO is
poly(ethylene oxide) and BO is poly(butylene oxide); Dow Company] and
0.852 g of Na2SO4 were dissolved in 30 g of pH 4.7 NaAc-HAc buffer
solution ([NaAc] = [HAc] = 0.40 M) under vigorous stirring overnight to
form a homogeneous solution at 10˚C. Then, 3.33 g of tetraethyl ortho-
silicate (TEOS) was added to the solution with continuous stirring for 24 h
at 10˚C. In step two, the reaction mixture was placed in an autoclave and
hydrothermally treated at 140˚C for another 24 h. The precipitate, con-
sisting of SVs, was filtered, repeatedly washed with deionized water to
remove the added salts, dried in air, and calcined at 550˚C in muffle fur-
nace (Carbolite) in air for 5 h. To modify SVs with octadecyl (-C18)
groups, 48 mg of calcined SVs were dispersed in 6 ml of toluene (Sigma-
Aldrich) in a 50-ml flask. The mixture was stirred at 110˚C for 6 h and
0.12 ml of n-octadecyltrimethoxysilane (Sigma-Aldrich) was added to the
mixture with stirring at 110˚C for 12 h. The SVs were recovered by
centrifugation, extensively washed with toluene and ethanol, and dried in a
fume-hood at room temperature.
The morphology of SV-140–C18 particles was observed using a field
emission scanning electron microscope (FE-SEM; JEOL JSM 7800) op-
erated at 0.8 kV. A sample-ethanol dispersion was dropped to an aluminum
foil piece, dried, and attached to the conductive carbon film on an FE-SEM
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mount. The FE-SEM mount was then cleaned by the plasma cleaner for
5 min before observation. For transmission electron microscopy observa-
tion, the sample-ethanol dispersion was dropped to the carbon film on a Cu
grid and dried. Nitrogen adsorption-desorption isotherms were measured
by using a Micromeritics Tristar II system at 2196˚C, before which the
sample was degassed at 100˚C overnight on a vacuum line. The total pore
volume was calculated from the amount adsorbed at a maximum relative
pressure (P/P0 = 0.99). The entrance size of SVs was calculated by the
Barrett–Joyner–Halanda method from the desorption branch of the iso-
therms and the specific surface area was calculated from the Brunauer–
Emmett–Teller method. Fourier transform infrared (FTIR) spectrum was
collected on a ThermoNicolet Nexus 6700 FTIR spectrometer equipped
with a Diamond Attenuated Total Reflection Crystal. Thirty-two scans
were collected for the spectrum at resolution of 4 cm21 in the range
400–4000 cm21.
Several characteristic peaks were found at 808, 1050–1200, 2852, and
2922 cm21 (Supplemental Fig. 1C), which can be attributed to symmetric
–Si-O-Si (24, 25) and antisymmetric -CH2- stretching of octadecyl groups
(26, 27), respectively.
SV-p67C–FITC confocal microscopy
An aliquot of s-p67C was labeled with a fluorescent FITC tag using an
FITC conjugation kit (Abcam), following the manufacturer’s instruc-
tions, hereafter referred to as s-p67C–FITC. SV-140–C18 SVs were
adsorbed with s-p67C–FITC (SV-p67C–FITC), as described above.
Murine macrophage-like RAW 264.7 cells (kindly donated by Dr. B. Rolfe
from the Australian Institute for Bioengineering and Nanotechnology, The
University of Queensland), were maintained in DMEM supplemented
with 10% FBS at 37˚C in a 5% CO2 incubator using standard cell culture
procedures.
For cellular uptake assays, 105 RAW 264.7 cells were allowed to attach
on sterile microscope coverslip chambers at 37˚C for 24 h and then ex-
posed to SV-140–C18 SVs, s-p67C–FITC, and SV-p67C–FITC, the last two
formulated with and without the adjuvant ISA 206 VG. Montanide ISA
206 VG adjuvant was mixed with Ag following the manufacturer’s in-
structions before exposing the mix to the cells. After 2 h of incubation at
37˚C and 5% CO2, the cells were washed three times with PBS pH 7.4.
Acidic organelles in the cells were stained red with Lysotracker Red DND-
99 (Thermo Fisher Scientific), cell membrane was stained with wheat germ
agglutinin, Alexa Fluor 647 conjugate (WGA-647; Thermo Fisher Scien-
tific) and nuclei were stained with Hoechst 33342 (Thermo Fisher Scien-
tific), following the manufacturer’s instructions. Cells were visualized
using a 403 confocal laser-scanning microscope (LSM510METS; Zeiss).
Microscopy was performed at the Australian Cancer Research Foundation
(ACRF)–Institute for Molecular Bioscience Cancer Biology Imaging Fa-
cility, which was established with the support of the ACRF.
Cattle immunogenicity and challenge studies
Holstein/Friesian and Ayrshire cattle (Bos taurus) from 6 to 9 mo old and
negative for T. parva Abs as determined by ELISA (28) were sourced from
farms in the Kenyan highlands. Animal experiments and routine mainte-
nance was in accordance with procedures approved by International
Livestock Research Institute’s (ILRI’s) Institute Animal Care and Use
Committee (experiment references 2016.15, 2016.24 for immunogenicity
studies, and 2017.23 for the challenge experiment).
For the immunogenicity studies, three animals were randomly assigned
to one of six experimental groups and each animal received three doses of
Ag, with 28-d intervals between booster doses (Table III). Animals received
a total of 2 ml per inoculation, administered s.c. in the neck, and were
monitored for adverse clinical reactions at the site of inoculation. All
immunogens (except for group 4) were diluted in PBS and mixed with
Montanide ISA 206 VG adjuvant (Seppic) in a 1:1 ratio following the
manufacturer’s instructions. In group 1, animals (BM005, BM062, and
BM065) were immunized with 100 mg of purified s-p67C fusion protein
(equivalent to 70 mg of p67C); group 2 (BM003, BM015, and BM073) and
group 4 animals (BM156, BM163, and BM189) were immunized with
100 mg of s-p67C adsorbed by 752 mg SV-140–C18 SVs (SV-p67C) with
and without adjuvant ISA 206 VG, respectively; group 3 animals (BM135,
BM162, and BM203) were immunized with 300 mg HBcAg-p67 VLPs,
equivalent to ∼80 mg p67C. Finally, group 5 (BN046, BN047, and BN048)
were immunized with the same amount of SV-67C and HBcAg-p67C
(from now called SV-HBc-p67C and equivalent to ∼150 mg of p67C)
separately formulated with ISA 206 VG and given as two inoculations, one
of each side of the neck; and group 6 (BN096, BN101, and BN120) were
inoculated with SV-HBc-p67C formulated with ISA206 VG together in a
single inoculation. None of the animals exhibited immediate or delayed
hypersensitivity, indicating safety of the Ag formulations. Samples of
blood for preparation of serum and PBMCs were taken at various times as
indicated in the text.
For the challenge experiment, 30 cattle were allocated in two groups of
15 each (Table III). Group 7 animals received three doses (with 28-d in-
tervals between booster doses) of SV-HBc-p67C (equivalent to ∼150 mg of
p67C), separately formulated with ISA 206 VG and given as two inocu-
lations, one of each side of the neck. Group 8 animals were kept unvac-
cinated to be used as a control group for challenge. A group of animals
vaccinated with HBcAg alone was not included, as it was previously
reported it has no effect on challenge outcome (29, 30). Twenty-one days
after the last boost, all animals were given an s.c. syringe challenge of 1 ml
of T. parva Muguga sporozoites (stabilate no. 3087), as previously de-
scribed (11). After the challenge, all experimental cattle were monitored
daily for changes in rectal temperatures and other clinical manifestations
of ECF, and the ECF scores were calculated (Rowland index) (31). The
index was used to define whether animals were susceptible (index: 6–10,
nonprotected) or immune (index: 0–5.99, protected) to ECF by the end of
the experiment, as previously described (7).
Statistical analysis for cattle in vivo experiments
The differences among immunogenicity groups in response to p67C was
also analyzed using a Kruskal–Wallis rank sum test, a nonparametric
method for testing whether samples originate from the same distribution.
Analysis of the immunity status of challenged animals was carried out
using both nonparametric and parametric methods. The immune animals, as
defined by the ECF scores described above, were first coded 1 and non-
immune animals were coded 0. The nonparametric difference in proportion
of animals immune between group 7 and group 8 was evaluated using a
Fisher exact test and exact 95% confidence intervals were calculated.
Subsequently, a parametric logistic regression was used to test the effect of
group, breed, and age on probability of immunity. As breed and age were
nonsignificant, the model was refit containing group only.
Analysis of the ECF scorewas also carried out using parametric methods.
Prior to statistical analysis of the final ECF scores, animals who reached the
humane end point (ECF score of 6.5) and were removed from the trial prior
to the end of the experiment (21 d after challenge) had their final ECF score
fixed at 6.5. Linear regression analysis was used to test for the differences in
ECF scores with group, breed, and age as explanatory variables. As with
immunity, the breed and age were nonsignificant. The regression was rerun
containing only the group effect and least-square mean final ECF score and
their 95% confidence intervals calculated for each group. The residuals were
checked to confirm the assumptions of the linear regression were appro-
priate, despite the fixed nature of animals who passed the humane end point
(6.5) these assumptions (linearity, normality, homoscedasticity, lack of
multicollinearity, and autocorrelation) were reasonable.
A Fisher exact test to assess the association between immunity and a
binary variable half-maximal (half-max) Ab titers and CD4 indices was also
performed to be able to assess the relationship of these two parameters,
separately and in combination, with protection. The half-max titer of 6000
and a CD4 index of 100 were selected as a cut-off for the association
because they are approximately the mean response of the immune animals
in group 7. For the combination variable, 1 = both half-max Ab titers and
CD4 indices above threshold versus 0 = all other combinations. A 95% exact
confidence interval was calculated around the observed immunity per-
centages for the above threshold half-max Ab titers, CD4 titers, and their
combination.
ELISAs for detection of Ab isotypes and sporozoite
seroneutralization assay
p67C-specific IgG and IgM Abs isotypes and IgG1 and IgG2 subtypes
responses were detected as previously described (11). Briefly, plates were
coated with 0.5 mg/ml of Ag in PBS for an ELISA and developed with
sheep anti-bovine IgG, IgM, IgG1, or IgG2 HRP-conjugated secondary
Abs (Bio-Rad Laboratories). Half-max Ab titers were calculated using OD
values from an Ab dilution series with Graph Pad Prism version 7.0b
(GraphPad software). HBcAg-specific Abs were detected in a similar assay
using HBcAg particles at 5 mg/ml in PBS as the coating Ag.
The ability of heat-inactivated bovine sera to inhibit in vitro infectivity of
the T. parva sporozoites was assessed using a 96-well seroneutralization
assay as previously described (11). Briefly, 1/50 dilutions of heat-
inactivated sera were incubated with T. parva sporozoites for 10 min.
Fresh Ficoll-isolated cattle PBMC were added to the mix and incubated for
1 h. Thereafter, plates were washed and resuspended in RPMI 1640 sup-
plemented with 10% heat-inactivated FBS and incubated for 14 d at 37˚C.
The read-out of the assay was based on an anti-PIM cellular ELISA, a
parasite Ag that is expressed by the schizont stage of the parasite. Sporozoite
neutralization results were expressed as the percentage of reduction of
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infectivity compared with infectivity rates in the presence of preimmuniza-
tion sera (day 0).
Serological specificity to overlapping p67C synthetic
linear peptides
Nine 15-mer peptides overlapping by 7 aa (Mimotopes Pty) were designed
to assess the peptide epitope specificity of sera from immunized animals
(Supplemental Table I). Immobilizer amino ELISA plates (Nunc Cell
Culture) were coated overnight at 4˚C with 10 mg/ml (100 ml per well) of
each peptide in 100 mM carbonate buffer (pH 9.6) (Sigma-Aldrich). After
incubation, plates were blocked for 1 h at 37˚C with PBS containing 0.05%
Tween 20 and 2% BSA (Sigma-Aldrich). After blocking, individual bovine
sera were added at 1/1000 dilution in blocking buffer and incubated
at 37˚C for 2 h. Thereafter, bovine Abs were detected using an HRP-
conjugated sheep anti-bovine IgG (AAI23P; Bio-Rad Laboratories) di-
luted 1/5000 in blocking buffer. After 1 h of incubation, the reaction was
developed for 10 min at 37˚C with 50 ml of TMB plus 2 (Kem-En-Tec
Diagnostics) and stopped using 50 ml of 0.5 M H2SO4 (Sigma-Aldrich).
Reactions were read at 450 nm using a Synergy HT ELISA Reader
(BioTek Instruments). Plates were washed four times in between each step
using PBS containing 0.05% Tween 20 and assays were carried out in
triplicates. The results presented as a heat map for the standardized OD
from individual animals with the average of the triplicates from each an-
imal and peptide was generated using the Heatmapper software (32). The
standardization was performed using the OD against a peptide pool con-
taining all linear peptides as a positive control.
CD4+ T cell IFN-g ELISpot and 3H-thymidine
proliferation assays
Assays were carried with CD4+ T cells that were enriched from Ficoll-
isolated PBMCs using magnetic beads (Miltenyi Biotec) coated with anti-
bovine CD4 ascites (ILRI mouse hybridoma clone ILA11), as previously
described (11).
IFN-g ELISpot assay on CD4+ T cells was as previously described (33).
Briefly, a monoclonal anti-bovine IFN-g Ab (MCA1783; Serotec) was
incubated overnight at 4˚C on ELISpot plates (MilliporeSigma), and then
blocked with RPMI 1640 supplemented with 10% FBS for 2 h at 37˚C
prior to adding specific Ag. Ags were tested in triplicates and two different
cell concentrations: 1.25 3 105 and 2.5 3 105 cell per well. The plates
were incubated at 37˚C for 20 h and developed using a rabbit polyclonal
anti-bovine IFN-g Ab (A2556; Sigma-Aldrich). Results were expressed as
IFN-g–secreting cell counts per million CD4+ cells (IFNg-SC per million
CD4+ cells). Two types of antigenic stimuli were used: s-p67C at 20 mg/ml
(equivalent to 2.5 mM) or a pool of seven 25-mer synthetic p67C peptides
at 2 mM (Supplemental Table I) that overlap by 16 aa residues covering the
p67C sequence (Mimotopes Pty). Media were used as a general negative
control, and 25-mer peptides not related to T. parva (Mimotopes Pty.) and
OVA (Sigma-Aldrich) were used as negative controls. Con A at 2.5 mg/ml
was used as a positive control.
CD4+ T cell proliferation to different Ags was analyzed in triplicates by
means of a 3H-thymidine CD4+ T cell proliferation assay, as previously
described (11). Briefly, CD4+ T cells (2 3 105 cells per well) were incu-
bated for 4 d at 37˚C in a CO2 incubator with the stimulus. Four stimuli
were used in this assay: s-p67C at 20 mg/ml (equivalent to 2.5 mM); a pool
of seven 25-mer synthetic p67C peptides at 2 mM (Supplemental Table I)
overlapping in 16 aa; and SV-p67C and HBcAg-p67C, each adjusted to an
equivalent amounts. Moreover, in this assay, two extra negative controls
were also included, apart from media alone, not–T. parva related peptides,
and OVA: SV-140–C18 empty SVs and HBcAg at 55 mg/ml (equivalent
amount of core Ag than into HBcAg-p67C). ConA at 2.5 mg/ml was used
as a positive control. The results were expressed as fold-increase resulting
from CPM-countsstimuli/CPM-countsmedia. Cells incubated with media
never had CPM values under 1022. As assays were carried out at different
times the fold-increase indices were standardized dividing the original
index by the ConA index (positive control) and multiplied by the average
of ConA indices from the different animals in different assays.
Results
HBcAg-p67C and control HBcAg VLP Ag production
and characterization
HBcAg-p67C and control HBcAg VLPs were purified under non-
denaturing conditions from bacterial cell lysates, folded into VLPs
and assessed using electron microscopy. Particles around 30–35 nm
with icosahedral-like symmetry were observed (Fig. 1A, 1B). An
mAb, ARIV21.4, which binds to an epitope on p67C (9) recognized
s-p67C and HBcAg-p67C but not HBcAg on Western blots (data not
shown). Average yields of ∼8.5 mg of s-p67C, ∼11 mg of HBcAg-
p67C VLPs, and ∼13 mg of HBcAg VLPs were obtained from 1 L of
E. coli cultures (Table I).
Production and characterization of SV-140–C18 SVs and
SV-p67C
To identify which type of SV particles efficiently adsorb s-p67C,
SVs with different diameters and surface chemistries were mixed
overnight at 4˚C with s-p67C in sterile PBS followed by p67C-
adsorption analysis of the SVs and supernatant. The s-p67C was
shown to adsorb to many of the SVs (Table II). The SV-140–C18
particles, which are 50 nm in diameter and surface modified with
octadecyl groups (-C18), were found to have the highest adsorption
capacity for s-p67C, with 1 mg of particles adsorbing 133 mg of
s-p67C.
SV-140–C18 were fabricated and characterized as previously
described (34). Electron microscope analyses revealed uniform
spheres with pores (Fig. 1C, 1D). The average particle diameter
and shell thickness were calculated to be 52.4 nm 6 5.1 nm and
5.7 nm 6 0.4 nm, respectively, with a pore size of 14.9 nm
(Supplemental Fig. 1A). The total pore volume and Brunauer–
Emmett–Teller surface area of the SV-140–C18 were 0.575 cm
3g21
and 131 m2g21, respectively (Supplemental Fig. 1B). The FTIR
spectrum of SV-140–C18 indicated the presence of octadecyl group
modifications on the silica surfaces (Supplemental Fig. 1C). A
typical round of synthesis yielded ∼800 mg of SV-140–C18
particles.
SV-p67C–FITC–labeled vesicles can access an acidic
intracellular compartment
To infer a possible intracellular fate of SV-p67C in vivo, we used
confocal microscopy to evaluate the in vitro interaction of a mouse
macrophage cell line, RAW 264.7, with s-p67C labeled with FITC
adsorbed to SV-140–C18 and costained with cellular markers.
No autofluorescence was observed in RAW 264.7 cells alone
FIGURE 1. Electron microscope (EM) images of VLPs and SV-140–C18.
Transmission EM analysis of (A) HBcAg-p67C VLPs, (B) HBcAg VLPs,
and (C) SV-140–C18, as well as (D) scanning EM analysis of SV-140–C18.
Arrows indicate entrances on the shells of SVs in both (C) and (D).
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(Fig. 2A) or in cells incubated with SV-140–C18 (Fig. 2B) as only
the endosomes (red), cell membrane (white), and the nuclei (blue)
were stained. Cells incubated with SV-p67C–FITC alone (Fig. 2C)
and following formulation with ISA 206 VG (Fig. 2D) resulted in
colocalization of Ag in an acidic compartment (orange and arrows
in Fig. 2C, 2D), which is likely to be part of the endosomal sys-
tem. This phenomenon was not observed either when incubating
the cells with s-p67C–FITC with or without ISA 206 VG.
High p67C-specific Ab responses were stimulated by
HBcAg-p67C, whereas SV-p67C stimulated higher CD4+
T cell responses in immunogenicity studies
We next carried out a series of immunogenicity studies with p67C in
the three different Ag formulations. Three Holstein/Friesian cattle
were assigned per experimental group (Table III), and group 1, 2,
and 3 animals were inoculated with s-p67C, SV-p67C, and
HBcAg-p67C, respectively, with each animal receiving an equiva-
lent of 70–80 mg of p67C Ag per inoculation mixed with ISA 206
VG adjuvant. Group 4 animals received SV-p67C without adjuvant.
Animals in group 3 developed an earlier and higher IgG Ab titers
to p67C than those in groups 1 and 2 (Fig. 3A–C). Although in-
dividual animal variation in Ab levels were observed in all groups,
there was a clear, positive effect associated with p67C inoculated as
VLPs (Fig. 3C). The average IgG half-max titers at day 77 in group
3 was approximately five times higher than the average titers in
groups 1 and 2 (Table IV). Although SVs provided an adjuvant
effect in sheep (35), in our studies, inoculation of SV-p67C without
ISA 206 VG gave a very poor Ab response (Fig. 3D), and the group
was not followed beyond day 70. No significant levels of IgM were
detected at any time point to day 77 in any of the treatment groups.
The longevity of the Ab response was monitored in groups 1–3 for
several weeks after the last Ag boost (Fig. 3). A multiphasic decay
of Abs was present in group 3, in which there was a sharp fall in Ab
levels after a peak at day 77, which was followed by stabilization of
Ab levels from day 91 to 119 and then another fall in Ab titer after
day 133. The Ab levels remained relatively stable from then to the
end of the experiment (day 175) (Fig. 3C). Increase in Ab titers
following each Ag dose were more modest in groups 1 and 2 and
only observed after the second Ag boost in group 2 but not until day
91 (Fig. 3B). Unexpectedly, sera from group 3 animals contained
very low levels of Abs to HBcAg VLPs (Supplemental Fig. 2).
To measure T cell responses to p67C, MACS bead–purified CD4+
T cells from cattle were stimulated with s-p67C protein or a pool of
25-mer p67C–overlapping synthetic peptides (Supplemental Table I).
A CD4+ T cell proliferation (Fig. 4A) and an IFN-g ELISpot assay
(Fig. 4B) were conducted at day 70. In both assays, the strongest
responses were observed in group 2, followed by group 1, with
groups 3 and 4 giving the lowest responses (Table V). To investigate
the longevity of T cell responses, the CD4+ proliferation assay was
repeated with samples collected at day 175, ∼4 mo, after the final Ag
dose (Fig. 4C). As before, animals from group 2 gave the highest
response, but they did not proliferate in response to SV-140–C18,
indicating that the SVs do not provide a nonspecific antigenic stim-
ulus in vitro. Cells from animals in group 3 proliferated mainly to
HBcAg, indicating that T cell responses were directed to hepatitis B
core Ag sequences rather than p67C in this Ag format. Chimeric
HBcAg VLPs have also been reported to prime Ag-specific CD8+
T cell responses (36). However, we were unable to measure a sig-
nificant IFN-g ELISpot response to overlapping p67C synthetic
25-mer peptides in an assay using purified CD8+ T cells from
cattle in groups 1, 2, or 3 (data not shown).
Simultaneous inoculation of SV-p67C and HBcAg-p67C
stimulated high p67C Ab and CD4+ T cell responses
To investigate if the HBcAg-p67C and SV-p67C formulations would
stimulate both arms of the immune response, we inoculated two groups
of cattle with these nanoparticles, delivered in the presence of adjuvant
as two simultaneous inoculations (group 5) or as a combined single
adjuvant formulation in one inoculation (group 6 and Table III). The
animals in groups 5 and 6 received an equivalent of 140–150 mg of
p67C Ag per inoculation, double the dose of p67C given to groups
1–4. The first inoculation strategy primed a strong p67C Ag-specific
Ab response (Fig. 3E), which was, on average, double the response
observed in group 6 (Fig. 3F, Table IV). Relative to the Ab levels in
group 5, the levels in group 6 dropped rapidly and were very low by
day 133 (Fig. 3F). Interestingly, the decay of Ab levels in group 5 was
much slower than that seen in group 3 (Fig. 3C, 3E), and in contrast
to group 3 cattle, two of the three animals in group 5 and all group 6
Table I. Amino acid sequence of proteins used in the experiments
Amino acid residues in red mark p67C sequences, and those in blue mark a linker sequence.
Table II. Summary of SV properties and assessment for p67C adsorption
SV Names Size (nm) Surface Charge Properties Entrance Pore Size
Relative Abundance of
Unbound s-p67C
SV-50 47.6 6 2.2 Negative Hydrophilic Small ++
SV-50–NH2 49.9 6 2.7 Positive Hydrophilic Small +++
SV-50–C18 50.7 6 3.1 Slightly negative Hydrophobic Small +++
SV-100 47.9 6 5.0 Negative Hydrophilic Medium ++
SV-100–NH2 49.1 6 1.9 Positive Hydrophilic Medium ++
SV-140 51.7 6 3.5 Negative Hydrophilic Large ++
SV-140–NH2 51.1 6 1.4 Positive Hydrophilic Large +++
SV-140-C18 52.4 6 5.1 Slightly negative Hydrophobic Large +
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animals developed a strong Ab response to HBcAg VLPs, indicating
that cattle can mount an Ab response to the viral Ag (Supplemental
Fig. 2). Both group 5 and group 6 cattle developed high levels of
p67C-specific CD4+ proliferative T cell responses (Fig. 4A). These
cattle also developed a T cell responses to HBcAg that were much
higher than those seen in group 3 (Fig. 4C). These results suggest that
coformulation of HBcAg-p67C with SV-p67C disrupts Ab responses
to the carrier proteins on the VLPs and that SVs may stimulate T cell
responses per se.
Anti-p67C Ab subtype responses and specificity to p67C
synthetic peptides
To assess Ab switching, we measured IgG1 and IgG2 ELISA
half-max titers to p67C at day 77 in cattle groups 1–6, except
group 4 as very poor Ab responses were detected in these an-
imals (Fig. 5A). IgG1 is the predominant IgG subtype
expressed in serum and milk in cattle (37), and it was the
dominant subtype response detected in the experimental groups
analyzed. An IgG2 response was only detected in group 3, 5,
and 6 cattle, which received HBcAg-p67C Ag and in one ani-
mal in group 1 (Table IV). Thus, cattle in groups 1 and 2
exhibited a skewed IgG1/IgG2 ratio, relative to those in groups
3, 5, and 6 (Fig. 5A).
Using the same sera, we also mapped the binding of total IgG
Ab in an ELISA to nine 15-mer synthetic peptides of p67C and
were overlapped by 7 aa residues (Supplemental Table I). An Ab
response to the peptides was detected with all sera, but the
pattern and strength of peptide recognition differed between
FIGURE 2. Confocal fluorescence microscopy of RAW 264.7 cells following incubation with SVs. The images are of (A) RAW 264.7 cells alone,
(B) cells with SV-140–C18, (C) cells with SV-p67C–FITC, (D) cells with SV-p67C–FITC in the presence of ISA 206 VG, (E) s-p67C–FITC, and (F)
s-p67C–FITC in the presence of ISA 206 VG. Acidic organelles in the cells were stained red with Lysotracker Red DND-99, cell membranes were
stained white with wheat germ agglutinin, Alexa Fluor 647 conjugate (WGA-647) and nuclei were stained blue with Hoechst 33342. FITC is
represented in green, and the colocalization of Ag in endosomes appears orange because of an overlap of red and green (white arrows indicate the
colocalization of Ag in the endosomes). The assays were performed in duplicate, and the best images are shown.
Table III. Summary of animal groups for immunogenicity studies (groups 1–6) and challenge experiments (groups 7 and 8)
Group Immunogen Doses Adjuvant
p67C (mg) per
Inoculation




Group 1 s-p67C 3 ISA 206 VG ∼70–80 100 3 N/A
Group 2 SV-p67C 3 ISA 206 VG ∼70–80 100 3 N/A
Group 3 HBcAg-p67C 3 ISA 206 VG ∼70–80 300 3 N/A
Group 4 SV-p67C 3 N/A ∼70–80 100 3 N/A
Group 5 SV-HBc-p67C
(two inoculations)
3 ISA 206 VG ∼140–150 400 3 N/A
Group 6 SV-HBc-p67C
(one inoculation)
3 ISA 206 VG ∼140–150 400 3 N/A
Group 7 SV-HBc-p67C
(two inoculations)
3 ISA 206 VG ∼140–150 400 15 LD93
Group 8 (challenge
control)
N/A N/A N/A N/A N/A 15 LD93
HBcAg-p67C, chimeric HBcAg VLPs displaying p67C; N/A, not applicable; SV-HBc-p67C, SV-p67C + HBcAg-p67C.
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animals, even within the same group (Fig. 5B). Peptide 6 and
peptide 7 contain the sequence SERQPSL and PSLVITD, re-
spectively, which have previously been identified as sites rec-
ognized by sporozoite-neutralizing mAbs (9). Ab binding to
these peptides by the cattle sera was also variable. Interest-
ingly, the pattern of peptides recognized by group 5 or 6 sera
did not represent a simple sum of the specificities present in
groups 2 and 3 (Fig. 5B).
Induction of sporozoite-neutralizing activity
Heat-inactivated day-77 sera diluted 1/50 from group 1, 2, 3, and
5 cattle were tested for their capacity to neutralize T. parva
sporozoite infectivity in vitro. Group 6 animals were not included
in this analysis because delivering the two nanoparticles in one
inoculum was not beneficial for immunity compared with group 5.
All sera had some degree of neutralizing activity (Fig. 5C,
Table VI) with the highest activity (from 48 to 87%) in sera from
animals in group 3 (BM135 and BM203) and group 5 (BN047 and
BN048). Preimmunization sera from day 0 had no neutralizing
capacity. The neutralizing capacity of the sera from group 2 was
similar to the animals in group 1 (Fig. 5C). We also measured the
sporozoite-neutralizing capacity of sera from group 2 animals at
day 91, corresponding to the delayed Ab peak, but this was no
higher than that at day 77 (Table VI). Sporozoite-neutralizing
FIGURE 3. Half-max p67C-specific total IgG Ab titers present in sera in cattle from the immunogenicity studies (three animals per group). Ab titers were
measured at different time points in individual animals in groups 1–6: (A) s-p67C, (B) SV-p67C, (C) HBcAg-p67C, (D) SV-p67C without ISA 206 VG
adjuvant, (E) SV-p67C + HBcAg-p67C as two separate inoculations, and (F) SV-p67C + HBcAg-p67C as one inoculation. The black arrows mark the day of
Ag inoculation. Note the difference in the y-axis scale for (A)–(D) versus (E) and (F).









Half-Max TitersDay 77 Day 91
Group 1 (s-p67C) BM005 3,127 4,943 3,207 3,207 Not detectable
BM062 2,792 2,734 2,600 2,600 Not detectable
BM065 3,256 1,761 12 3,150 255
Group 2 (SV-p67C) BM003 4,757 11,342 5,000 5,000 Not detectable
BM015 1,329 3,546 1,246 1,246 Not detectable
BM073 2,921 5,216 3,100 3,100 Not detectable
Group 3 (HBcAg-p67C) BM135 12,337 5,461 7 12,274 1,682
BM162 10,568 2,460 15 11,345 753
BM203 17,883 6,858 8 16,394 2018
Group 4 (SV-p67C without ISA 206 VG) BM156 76a N/A N/A N/A N/A
BM163 265a N/A N/A N/A N/A
BM189 105a N/A N/A N/A N/A
Group 5 (SV-HBc-p67C, two inoculations) BN046 10,087 8,410 13 11,200 862
BN047 27,652 29,544 3 25,400 8,830
BN048 10,715 10,671 3 9,987 3,782
Group 6 (SV-HBc-p67C, one inoculation) BN096 14,523 9,884 11.87 8,895 750
BN101 3,299 1,317 18.12 3,800 210
BN120 4,983 10,641 4.39 6,354 1,447
aDay 70 p67C-specific IgG half-max Ab titers.
ID, identifier; N/A, not applicable.
The Journal of Immunology 7
activity was found in group 3 and group 5 sera as early as day 14,
but only at day 28 in groups 1 and 2 (Table VI).
Protection to ECF in cattle inoculated with SV-p67C and
HBcAg-p67C as separate formulations
Because only group 5 cattle had high Ab levels with a switch to
IgG2 and strong CD4+ T cell responses to p67C, we designed an
experiment to test the vaccine efficacy of the combination of the
two delivery systems, SV-p67C and HBcAg-p67C, from now
called “SV-HBc-p67C.” Fifteen Holstein/Friesian cattle (group 7)
were immunized as described for group 5 (Table III). The total
IgG Ab response (Fig. 6A), CD4+ proliferative T cell responses
(Fig. 6B), IgG1 and IgG2 subtypes (Fig. 6C), and Ab specificity
to synthetic p67C peptides (Fig. 6D) were measured in the
immunized cattle (Table VII). All cattle developed IgG and
T cell responses to p67C and an Ab response to HBcAg VLPs
(Supplemental Fig. 2). However, on average, the total IgG levels
to p67C across group 7 cattle were lower than those measured in
the group 5 animals (Fig. 3E), and except for one animal, both
IgG1 and IgG2 subtypes were present and very balanced in all
animals (Fig. 6C, Table VII).
Group 7 cattle were given a needle sporozoite challenge 21 d
after the last Ag boost. Fifteen naive cattle (group 8) served as a
sporozoite challenge control (Table III). Animals were clinically
monitored and an ECF index calculated from the onset of pyrexia
(31). An adjuvant control group and animals immunized with
HBcAg alone was not included, as it has been previously shown
that it does not influence the outcome of challenge (7, 29, 30),
although we cannot rule out a minimal adjuvating effect. The
experiment was unblinded on day 21 postchallenge. Animals with
a Rowland’s ECF index of 6 and above were classified as sus-
ceptible to ECF (11, 31). Ten animals, nine in group 7 and one
in group 8, were classified as immune to challenge (Fig. 6F,
Table VIII). Relative to the control group, which experienced an
approximately LD93 challenge (the highest used with p67C), the
vaccine efficacy in group 7 was calculated to be ∼53%. A robust
significant difference was found when comparing the ECF scores
from groups 7 and 8 (p = 0.004) using linear regression. This
effect was unchanged (p = 0.003) when including breed and age in
the model, as both were not important (p = 0.140 and p = 0.233,
respectively). Moreover, the protection difference between the
two groups analyzed by a nonparametric Fisher exact test is also
FIGURE 4. The responses of enriched CD4+ T cell from immunized cattle to different stimuli were measured in cattle from the immunogenicity studies
(three animals per group). (A) The p67C-specific proliferative cellular response in individual animals in groups 1–6 (Kruskal–Wallis p , 0.05) and (B)
p67C-specific IFN-g–secreting cells per million CD4+ T cells in individual animals in groups 1–4 were measured at 2 wk after the last boost at day 70
(Kruskal–Wallis p , 0.05). (C) T cell proliferative responses were measured in individual animals in groups 1–3 and groups 5 and 6 at day 175 to different
stimuli. Ag stimuli used were the following: p67C peptide pool (a pool of 25-mer p67C–overlapping peptides), s-p67C, SV-p67C, SV-140–C18 SVs,
HBcAg-p67C, and HBcAg VLPs. The group average and SD are also shown.





Million CD4+ T Cellsa
Group 1 (s-p67C) BM005 83.66 422.42
BM062 307.41 739.84
BM065 14.51 150.10
Group 2 (SV-p67C) BM003 208.71 3372.13
BM015 142.37 683.80
BM073 238.92 2467.90
Group 3 (HBcAg-p67C) BM135 7.31 328.91
BM162 7.64 205.93
BM203 2.54 92.14
Group 4 (SV-p67C without ISA 206 VG) BM156 4.8 80.98
BM163 3.6 40.01
BM189 2.8 51.72
Group 5 (SV-HBc-p67C, two inoculations) BN046 197.15 887.78
BN047 291.45 1861.57
BN048 131.62 2901.23
Group 6 (SV-HBc-p67C, one inoculation) BN096 352.28 N/A
BN101 316.87 N/A
BN120 258.66 N/A
aUsing p67C protein at 2.5 mM as stimuli at day 70.
ID, identifier; N/A, not applicable.
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strongly significantly different between the two groups (p = 0.005).
Parametric logistic regression showed similar significance of dif-
ference in immunity (p = 0.009) and, again, the breed and age of
the animals were of no importance (p = 0.994 and p = 0.902,
respectively) (Table VIII).
It is important to highlight one animal in group 8 was classified
as immune to ECF because of spontaneous recovery following
clinical infection (ECF score of 3.05). This is a well-described
phenomenon, as the severity of ECF is sporozoite dose depen-
dent and there is a variation in the threshold of infectivity for
individual animals (38, 39). In contrast, six of the ECF immune
cattle in group 7 had an ECF score of,1.4 and the other three had
a score between 4.5 and 5.99 (Table VIII). Taking into account
that ECF is a dose-dependent disease and historically, the maxi-
mum challenge dose was an LD70 (whereas we are challenging
with double the amount of sporozoites to get an LD93), and
keeping in mind we are using three times less Ag than in previous
experiments (7, 10, 11), the combination of SV-HBc-p67C pro-
vided an improvement in vaccine efficacy and it is a very prom-
ising immunization regimen.
A statistical analysis was performed to assess the association
between immunity and Ab titers and CD4 indices individually or in
combination. Both parameters individually showed nonsignificant
association with immunity, Fisher test p = 0.608 for Ab titers and
0.287 for CD4 index. However, in combination, a significant as-
sociation was observed (p = 0.043). Ab titers higher than 6000
indicated a survival rate of 71% (LD93 challenge), whereas a CD4
index higher than 100 indicated that 83% of the cattle are immune.
When the two previous parameters threshold are true and they are
taken in combination (Abs . 6000 and CD4 .100), the level of
immunity observed was 100%. Unfortunately, because of the
variability in responses among the animals, the confidence inter-
vals for these parameters are large (Table VIII). Although this
makes the power of predictability weaker, it indicates the impor-
tance of Abs and CD4 responses to protect against ECF. However,
further investigations are needed to increase the strength of their
association.
Discussion
The use of nanotechnology in vaccinology has been increasing
exponentially in the past decade (40), leading to the birth of
“nanovaccinology” (41). Particulate Ags are often more immu-
nogenic than those in a soluble form, and nanotechnology offers
an opportunity to design Ag-containing nanoparticles that vary in
composition, size, shape, and surface properties to boost the an-
tigenicity of candidate vaccine Ags and modulate immune re-
sponses. HBcAg VLPs and 50 nm SV-140–C18 SVs are two
nanoparticle technologies that are reported to function as superior
FIGURE 5. Anti-p67C Ab subtype responses, specificity to p67C synthetic peptides, and sporozoite-neutralizing activity in immunogenicity studies
(three animals per group). (A) Serum samples from cattle at day 77 after the first Ag dose were used to measure IgG subtype responses, and the p67C-
specific Ab IgG1/IgG2 ratios in sera from individual animal in groups 1–3 and 5–6 are shown. (B) Reactivity of the same sera with synthetic overlapping
p67C peptides using a color-coded heat map generated with Heatmapper software based on peptide reactivity. (C) Sporozoite neutralization capacity of
serum from individual animals and the group average and SD of sera from groups 1, 2, 3, and 5.
Table VI. Summary results of the percentage of neutralization capacity of sera from animals under immunogenicity studies in cattle
Group Animal ID Day 14 Day 28 Day 77 Day 91
Group 1 (s-p67C) BM005 0 32 23 17
BM062 0 20 11 6
BM065 0 9 6 3
Group 2 (SV-p67C) BM003 0 22 11 13
BM015 0 19 20 10
BM073 0 9 22 10
Group 3 (HBcAg-p67C) BM135 23 47 48 40
BM162 23 13 24 19
BM203 20 13 51 60
Group 5 (SV-HBc-p67C, two inoculations) BN046 8 2 36 14
BN047 12 28 87 81
BN048 26 30 75 54
ID, identifier.
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Ag delivery systems (12, 16). Our objective was to evaluate the
capacity of both platforms to improve the immunogenicity and
vaccine potential of an 80-aa domain of the p67 Ag from T. parva
called p67C (8).
In this study, we describe successful generation of HBcAg-p67C
VLPs using a glycine-rich linker sequence that flanked p67C
cloned into the major immunodominant region of the HBcAg,
overcoming the length limitation that the system faced previously
with other T. parva Ags (22). Conceptually, SV nanoparticles offer
a simpler technology as overnight incubation with an Ag results in
its adsorption to the SVs and generation of particulate Ag, albeit in
a different format to that by VLPs (23, 34). Altering the surface
chemistry of SV-140 to create a hydrophobic surface property by
adding -C18 functional groups to them resulted in optimal ad-
sorption of s-p67C. In contrast, in a study with the E2 Ag of
BVDV-1, the nonfunctionalized SVs gave the highest level of Ag
adsorption (23), pointing out there is not a gold-standard SV and,
therefore, specific Ags must be tested with a variety of SVs to find
the optimal nanoparticle.
Assessment of Ag-specific Ab and CD4+ T cell responses has
been informative on the performance of the individual VLP and
SV Ag delivery systems and their intrinsic properties in stimu-
lating different arms of the immune response. HBcAg-p67C VLPs
with a T = 4 symmetry are predicted to contain 120 dimeric
subunits and should display 240 copies of p67C (42). It is rea-
sonable to speculate that the display of p67C at high-density and
FIGURE 6. Immune response and protection achieved in group 7 (three doses of HBcAg-p67C/SV-p67C) and group 8 (challenge control) animals, 15
animals per group. (A) Kinetics of Ag-specific IgG Ab titers measured in sera, average (n = 15), and SD are shown. The days of Ag injection are represented
by black arrows. (B) p67C-specific CD4+ T cell proliferation increases were measured at 2 wk after the last boost (day 70), individual animals (n = 15), the
group average, and SD are shown. Two different stimuli were used: a pool of 25-mer p67C–overlapping peptides (Pept.) and s-p67C. Negative stimulus
responses are also included: ovalbumin (ovoalb.) and irrelevant peptides (irr. pept.). (C) p67C-specific Ab IgG1/IgG2 ratios in sera from individual animals.
(D) A color-coded heat map based on peptide recognition by sera from individual animals is shown. Animals are separated in immune and susceptible
groups after challenge. (A–D) Group 7 results. (E) ECF scores of both groups of animals, the mean and the 95% confidence interval are shown. A red line
separates the protected and nonprotected animals (ECF score $ 6). The significance of the differences among groups is also shown. **p , 0.01.
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in a regular array on the VLPs results in improved cross-linking of
surface Ig and B cell activation (12, 42, 43), resulting in the high
p67C Ab response that included a switch to an IgG2 subtype.
Unlike in other species, there is no clear evidence for a major
difference in the functional role of bovine IgG1 and IgG2. Both
subtypes can fix complement, although there are some differences
in their opsonizing capacity with superior performance associated
with IgG2 (44). Bovine allotypic variants of IgG1, IgG2, and IgG3
have been described (45–48), but reagents to assay them are not
available. Thus, little is known about their functional importance.
Interestingly enough, the high Ab responses were not in agree-
ment with the CD4+ T cell responses in this group of animals, as
the cellular responses were directed mainly to the HBcAg poly-
peptide sequences. Such bias in the cellular immune response to
chimeric VLPs has also been described in other studies (14, 49).
The SV-p67C nanoparticle represents an immunologically in-
teresting delivery platform as Ag is adsorbed on the external and
internal surfaces of the particle. This interaction is stable and most
likely results in creating an Ag depot (50). Priming of an Ab re-
sponse could occur by direct interaction of B cells with p67C at
the surface of the SV or via interaction with soluble Ag that is
released from the particles. However, the former, if it occurs, does
not promote an Ab switch and the latter may contribute to the
delayed peak of the Ab response to the last SV-p67C Ag boost at
day 91 instead of day 77, as seen with HBcAg-p67C and s-p67C.
Ag bound to the internal surfaces is likely to be protected from
degradation and the subsequent endocytosis of the SV-p67C into
professional APCs, may facilitate intact p67C entering the MHC
class II Ag-processing and presentation pathway via the endo-
somal system (51), resulting in the strong CD4+ T cell response
detected in this study. Indeed, using confocal fluorescence mi-
croscopy, we demonstrated that the SV-p67C–FITC preparations
can be trafficked into an acidic compartment of cells in in vitro
experiments. We did not detect CD4+ T cell proliferative re-
sponses to empty SVs, indicating that the particles do not provide
nonspecific stimuli to these cells in in vitro assays. Silica nano-
particles have been shown to activate a proinflammatory cytokine
response (52, 53), a pathway also exploited by widely used com-
mercial adjuvants (54, 55). This could contribute in vivo to the
enhanced p67C-specific immune responses primed by SV-p67C
observed in this study.
The addition of an adjuvant had no effect on the immune re-
sponse to the E2 Ag of BVDV-1 delivered by SVs to sheep (35) or
mice (23) in immunogenicity studies. In these studies, there were
no detectable differences in the quantity of the Ab or cellular
immune responses primed with or without the use of Quil-A as an
adjuvant. In contrast, in the current study, inoculation of cattle
with SV-p67C without ISA 206 VG primed very poor Ab and
CD4+ responses. But the inclusion of the adjuvant ISA 206 VG
stimulated a balanced immune response, indicating that the pos-
sible enhancing effect of the SVs, is further potentiated by this
adjuvant. The capacity of SVs to enhance the immune response
may be related to whether the adsorbed Ag is a good or poor
immunogen (e.g., the E2 Ag of BVDV-1 and s-p67C polypeptide,
respectively). However, it is likely that other factors influenced the
outcome. The interaction between the different Ags with the SV
nanoparticles may play a critical role, affecting the release prop-
erties of the adsorbed Ag from the SV after cellular uptake. Based
on this hypothesis, the p67C molecules may be strongly adsorbed
to the SV-140–C18 particles and the adjuvant ISA 206 VG could
act to increase the cell uptake, making both mechanisms in-
dispensable for successfully eliciting an immune response. In
contrast, the E2 Ag may be efficiently released from the SVs
following cellular uptake and efficiently presented on the cell
surface. It may explain why a conventional adjuvant was not
required for E2 Ag (35).
To stimulate both high Ab and T cell p67C responses, we in-
oculated cattle with p67C Ag in the two different nanoparticle
technologies of interest to this study. Simultaneous inoculation of
HBcAg-p67C and SV-p67C gave rise to balanced immune re-
sponses when the immunogens were formulated with ISA 206 VG
and injected as two separate inoculations. In contrast, lower im-
mune responses resulted when the two immunogens were for-
mulated as one inoculation. We speculate that destabilization of the
VLPs in this formulation leads to loss of p67C immunogenicity.
This hypothesis is supported by the differences in the immune
parameters we measured in groups 5 and 6 including a higher Ab
response to HBcAg in the latter group. However, it remain to be
explored the possibility to formulate the two immunogens sepa-
rately with adjuvant and mix them in one inoculum before
injection.
Our observations raised the possibility that coinoculation with
that same Ag via two nanoparticle technologies may act syner-
gistically to elicit ideal protective immune responses and provide
superior protection to that induced by three inoculations of 450 mg
s-p67C with ISA 206 VG, in which ∼50% cattle were immune to
an LD70 sporozoite challenge (11). Hence, we immunized 15
cattle with three doses of HBcAg-p67C and SV-p67C (equivalent of








BN077 13,700 4.21 105.84
BN085 3,033 8.17 5.86
BN086 5,579 8.25 196.68
BN092 1,823 5.45 29.9
BN093 2,590 3.83 51.59
BN094 2,747 5.99 14.74
BN097 2,443 22.40 21.61
BN099 2,776 13.53 38.62
BN100 8,575 6.36 82.75
BN103 6,281 88.24 90.61
BN104 11,344 10.31 99.37
BN107 5,928 7.81 30.27
BN108 6,030 10.49 87.65
BN113 9,752 12.28 174.75
BN115 6,922 11.03 319.37
aUsing p67C protein at 2.5 mM as stimuli at day 70.
ID, identifier.
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140–150 mg of s-p67C per dose) formulated separately. As expected
from the immunogenicity studies, the two nanoparticle systems
stimulated both p67C-specific Ab and CD4+ T cell responses in all
15 cattle, corroborating not only that the two delivery systems did
not compete, but they acted synergistically to generate balanced
immune responses. This is in line with a previous study in mice,
which used Ad5/MERS and boosted with spike protein nano-
particles and they found that balanced Ab and cell-mediated re-
sponses were generated (56). Importantly, in the current study, upon
challenge, ∼53% of the cattle were immune to an approximately
LD93 sporozoite challenge, which is the highest challenge dose used
to test p67C protective capacity and using more than three times
less p67C Ag to date (7, 10, 11). ECF is a dose-dependent disease
and the animals in the challenge experiment got double the amount
of sporozoites compared with any of the previous published ex-
periments (7, 10, 11), the immune response generated specifically
against p67C had to fight a significantly higher parasite load to get
53% of the animals protected. Moreover, the outcome of the chal-
lenge experiment allowed an assessment of the association between
the Ab titers and the CD4 indices with protection. The association
of both parameters with protection individually was NS. However,
when the two parameters were taken in combination, the association
was significant with an observed level of immunity of 100%, in-
dicating that both immune parameters are associated with protection
against ECF. However, further investigations are needed to assess
the individual associations of the immune parameters with protec-
tion. This is a work in progress and a priority in ECF research.
The findings reported in this study support the combined use of
VLPs and SV technology as a novel vaccination strategy to enhance
the immunogenicity of otherwise poor Ags in large animal vaccine
studies. In the current study, the nanoparticle platforms acted
synergistically for enhanced efficacy against a complex parasite
like T. parva. The simplicity of SVs to adsorb and deliver an Ag
without measurable adverse reactions, combined with low
manufacturing cost, make them a very attractive platform for Ag
delivery. These results also demonstrate the huge potential of the
use of VLPs for the future development of improved vaccines
against ECF. The immune responses could be further improved
to achieve a higher vaccine efficacy with two doses of Ag or
the inclusion of other sequences from p67 that contain addi-
tional sporozoite-neutralizing sites (9, 10). Moreover, it has been
demonstrated that heterologous prime-boost vaccination regimen
Table VIII. Summary of protection results and statistical analysis of protection and ECF score differences between groups 7 and 8
*Final ECF score set to 6.5 (humane end point).
**Half-max Ab titers at day 77 and CD4 proliferation indices at day 77 using 25-mer overlapping peptides as stimuli.
***Comparison with Ab titer #6,000; CD4 index #100; and combinaton = low for both or either.
****Combination of the two parameters in which both thresholds (Ab titer . 6000 and CD4 index . 100) need to be true for protection association.
CI, confidence interval; ID, identifier; Imm., immune; sig., significant; Susc. susceptible.
12 SYNERGISTIC NANOPARTICLE EFFECT ENHANCING PROTECTION TO ECF
could enhance the immune response to certain Ags (reviewed in
Ref. 57). These are aspects that will be explored in future studies.
These nanoparticle technologies have the potential to underpin the
development of a more cost-effective and robust vaccine to im-
prove the control of ECF, the most important disease affecting
cattle in sub-Saharan Africa.
Acknowledgments
We thank the ILRI Farm staff for animal maintenance and the ILRI Tick
Unit for provision of T. parva sporozoites and dissected tick salivary
glands, and Dr. I. Pintelon, University of Antwerp, for technical help with
electron microscopy. We thank Dr. N. Condon for technical help with
confocal microscopy, which was performed at the ACRF/Institute for Mo-
lecular Bioscience Cancer Biology Imaging Facility, which was estab-
lished with the support of the ACRF.
Disclosures
The authors have no financial conflicts of interest.
References
1. Norval, R., B. Perry, and A. Young. 1992. The Epidemiology of Theileriosis in
Africa. Academic Press Limited, London.
2. Perry, B. D. 2016. The control of East Coast fever of cattle by live parasite
vaccination: a science-to-impact narrative. One Health 2: 103–114.
3. Pearson, T. W., L. B. Lundin, T. T. Dolan, and D. A. Stagg. 1979. Cell-mediated
immunity to Theileria-transformed cell lines. Nature 281: 678–680.
4. McKeever, D. J., E. L. Taracha, E. L. Innes, N. D. MacHugh, E. Awino,
B. M. Goddeeris, and W. I. Morrison. 1994. Adoptive transfer of immunity to
Theileria parva in the CD8+ fraction of responding efferent lymph. Proc. Natl.
Acad. Sci. USA 91: 1959–1963.
5. Morrison, W. I., T. Connelley, J. D. Hemmink, and N. D. MacHugh. 2015.
Understanding the basis of parasite strain-restricted immunity to Theileria parva.
Annu. Rev. Anim. Biosci. 3: 397–418.
6. Musoke, A., S. Morzaria, C. Nkonge, E. Jones, and V. Nene. 1992. A
recombinant sporozoite surface antigen of Theileria parva induces protection in
cattle. Proc. Natl. Acad. Sci. USA 89: 514–518.
7. Musoke, A., J. Rowlands, V. Nene, J. Nyanjui, J. Katende, P. Spooner,
S. Mwaura, D. Odongo, C. Nkonge, S. Mbogo, et al. 2005. Subunit vaccine
based on the p67 major surface protein of Theileria parva sporozoites reduces
severity of infection derived from field tick challenge. Vaccine 23: 3084–3095.
8. Nene, V., H. Kiara, A. Lacasta, R. Pelle, N. Svitek, and L. Steinaa. 2016. The
biology of Theileria parva and control of East Coast fever - current status and
future trends. Ticks Tick Borne Dis. 7: 549–564.
9. Nene, V., E. Gobright, R. Bishop, S. Morzaria, and A. Musoke. 1999. Linear
peptide specificity of bovine antibody responses to p67 of Theileria parva and
sequence diversity of sporozoite-neutralizing epitopes: implications for a vac-
cine. Infect. Immun. 67: 1261–1266.
10. Bishop, R., V. Nene, J. Staeyert, J. Rowlands, J. Nyanjui, J. Osaso, S. Morzaria,
and A. Musoke. 2003. Immunity to East Coast fever in cattle induced by a
polypeptide fragment of the major surface coat protein of Theileria parva spo-
rozoites. Vaccine 21: 1205–1212.
11. Lacasta, A., S. Mwalimu, E. Kibwana, R. Saya, E. Awino, T. Njoroge, J. Poole,
N. Ndiwa, R. Pelle, V. Nene, and L. Steinaa. 2018. Immune parameters to p67C
antigen adjuvanted with ISA206VG correlate with protection against East Coast
fever. Vaccine 36: 1389–1397.
12. Pumpens, P., R. E. Ulrich, K. Sasnauskas, A. Kazaks, V. Ose, and E. Grens.
2008. Construction of novel vaccines on the basis of virus-like particles: hepa-
titis B virus proteins as vaccine carriers. In Medicinal Protein Engineering. Y. E.
Khudyakov, ed. CRC Press, Boca Raton, FL, p. 204–248.
13. Brown, A. L., M. J. Francis, G. Z. Hastings, N. R. Parry, P. V. Barnett,
D. J. Rowlands, and B. E. Clarke. 1991. Foreign epitopes in immunodominant
regions of hepatitis B core particles are highly immunogenic and conforma-
tionally restricted. Vaccine 9: 595–601.
14. Boulter, N. R., E. J. Glass, P. A. Knight, L. Bell-Sakyi, C. G. Brown, and R. Hall.
1995. Theileria annulata sporozoite antigen fused to hepatitis B core antigen
used in a vaccination trial. Vaccine 13: 1152–1160.
15. Huang, Y., W. Liang, Y. Wang, Z. Zhou, A. Pan, X. Yang, C. Huang, J. Chen, and
D. Zhang. 2005. Immunogenicity of the epitope of the foot-and-mouth disease
virus fused with a hepatitis B core protein as expressed in transgenic tobacco.
Viral Immunol. 18: 668–677.
16. Mody, K. T., A. Popat, D. Mahony, A. S. Cavallaro, C. Yu, and N. Mitter. 2013.
Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine
delivery. Nanoscale 5: 5167–5179.
17. Zhang, J., S. Karmakar, M. Yu, N. Mitter, J. Zou, and C. Yu. 2014. Syn-
thesis of silica vesicles with controlled entrance size for high loading,
sustained release, and cellular delivery of therapeutical proteins. Small 10:
5068–5076.
18. Zhao, L., D. Mahony, A. S. Cavallaro, B. Zhang, J. Zhang, J. R. Deringer,
C. X. Zhao, W. C. Brown, C. Yu, N. Mitter, and A. P. J. Middelberg. 2016.
Immunogenicity of outer membrane proteins VirB9-1 and VirB9-2, a novel
nanovaccine against anaplasma marginale. PLoS One 11: e0154295.
19. Mody, K. T., D. Mahony, A. S. Cavallaro, J. Zhang, B. Zhang, T. J. Mahony,
C. Yu, and N. Mitter. 2015. Silica vesicle nanovaccine formulations stimulate
long-term immune responses to the Bovine Viral Diarrhoea Virus E2 protein.
[Published erratum appears in 2016 PLoS One 11: e0146631.] PLoS One 10:
e0143507.
20. Broos, K., P. Vanlandschoot, M. Maras, J. Robbens, G. Leroux-Roels, and
Y. Guisez. 2007. Expression, purification and characterization of full-length
RNA-free hepatitis B core particles. Protein Expr. Purif. 54: 30–37.
21. Guex, N., M. C. Peitsch, and T. Schwede. 2009. Automated comparative protein
structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical
perspective. Electrophoresis 30(Suppl. 1): S162–S173.
22. Janssens, M. E., D. Geysen, K. Broos, I. De Goeyse, J. Robbens, F. Van Petegem,
J. P. Timmermans, and Y. Guisez. 2010. Folding properties of the hepatitis B
core as a carrier protein for vaccination research. Amino Acids 38: 1617–1626.
23. Mody, K. T., D. Mahony, J. Zhang, A. S. Cavallaro, B. Zhang, A. Popat,
T. J. Mahony, C. Yu, and N. Mitter. 2014. Silica vesicles as nanocarriers and
adjuvants for generating both antibody and T-cell mediated immune resposes to
Bovine Viral Diarrhoea Virus E2 protein. Biomaterials 35: 9972–9983.
24. Mahadik, D. B., A. V. Rao, A. P. Rao, P. B. Wagh, S. V. Ingale, and S. C. Gupta.
2011. Effect of concentration of trimethylchlorosilane (TMCS) and hexame-
thyldisilazane (HMDZ) silylating agents on surface free energy of silica aero-
gels. J. Colloid Interface Sci. 356: 298–302.
25. Yao, Y., J. Cao, M. Yang, J. Li, S. Zhao, W. Yin, Y. Li, X. He, and J. Leng. 2013.
Exploration of the novel stacked structure and one-step fabrication of electrospun
silica microbelts with controllable wettability. RSC Advances 30: 2335–2345.
26. Huang, H., C. Yang, H. Zhang, and M. Liu. 2008. Preparation and character-
ization of octyl and octadecyl-modified mesoporous SBA-15 silica molecular
sieves for adsorption of dimethyl phthalate and diethyl phthalate. Microporous
Mesoporous Mater. 111: 254–259.
27. Kailasam, K., and K. Müller. 2008. Physico-chemical characterization of MCM-
41 silica spheres made by the pseudomorphic route and grafted with octadecyl
chains. J. Chromatogr. A. 1191: 125–135.
28. Morzaria, S. P., J. Katende, A. Musoke, V. Nene, R. Skilton, and R. Bishop.
1999. Development of sero-diagnostic and molecular tools for the control of
important tick-borne pathogens of cattle in Africa. Parassitologia 41(Suppl. 1):
73–80.
29. Wu, Y., R. Zhu, L. Xu, Y. Li, S. Li, H. Yu, S. Li, H. Zhu, T. Cheng, and N. Xia.
2017. A novel combined vaccine based on monochimeric VLP co-displaying
multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Vaccine 35: 2728–2735.
30. Huo, C., J. Yang, L. Lei, L. Qiao, J. Xin, and Z. Pan. 2017. Hepatitis B virus core
particles containing multiple epitopes confer protection against enterovirus 71
and coxsackievirus A16 infection in mice. Vaccine 35: 7322–7330.
31. Rowlands, G. J., A. J. Musoke, S. P. Morzaria, S. M. Nagda, K. T. Ballingall, and
D. J. McKeever. 2000. A statistically derived index for classifying East Coast
fever reactions in cattle challenged with Theileria parva under experimental
conditions. Parasitology 120: 371–381.
32. Babicki, S., D. Arndt, A. Marcu, Y. Liang, J. R. Grant, A. Maciejewski, and
D. S. Wishart. 2016. Heatmapper: web-enabled heat mapping for all. Nucleic
Acids Res. 44(W1): W147–W153.
33. Steinaa, L., R. Saya, E. Awino, and P. Toye. 2012. Cytotoxic T lymphocytes
from cattle immunized against Theileria parva exhibit pronounced cross-
reactivity among different strain-specific epitopes of the Tp1 antigen. Vet.
Immunol. Immunopathol. 145: 571–581.
34. Yang, Y., M. Jambhrunkar, P. L. Abbaraju, M. Yu, M. Zhang, and C. Yu. 2017.
Understanding the effect of surface chemistry of mesoporous silica nanorods on their
vaccine adjuvant potency. Adv. Healthc. Mater. DOI: 10.1002/adhm.201700466.
35. Mahony, D., K. T. Mody, A. S. Cavallaro, Q. Hu, T. J. Mahony, S. Qiao, and
N. Mitter. 2015. Immunisation of sheep with bovine viral diarrhoea virus, E2
protein using a freeze-dried hollow silica mesoporous nanoparticle formulation.
PLoS One 10: e0141870.
36. Ferrari, C., A. Bertoletti, A. Penna, A. Cavalli, A. Valli, G. Missale, M. Pilli,
P. Fowler, T. Giuberti, F. V. Chisari, and F. Fiaccadori. 1991. Identification
of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid anti-
gen. J. Clin. Invest. 88: 214–222.
37. Butler, J. E. 1998. Immunoglobulin diversity, B-cell and antibody repertoire
development in large farm animals. Rev. Sci. Tech. 17: 43–70.
38. Cunningham, M. P., C. G. D. Brown, M. J. Burridge, A. J. Musoke, R. E. Purnell,
D. E. Radley, and C. Sempebwa. 1974. East Coast fever: titration in cattle of
suspensions of Theileria parva derived from ticks. Br. Vet. J. 130: 336–345.
39. Dolan, T. T., A. S. Young, G. J. Losos, I. McMilian, C. E. Minder, and
K. Soulsby. 1984. Dose dependent responses of cattle to Theileria parva stabi-
late. Int. J. Parasitol. 14: 89–95.
40. Zhao, L., A. Seth, N. Wibowo, C. X. Zhao, N. Mitter, C. Yu, and A. P.
J. Middelberg. 2014. Nanoparticle vaccines. Vaccine 32: 327–337.
41. Mamo, T., and G. A. Poland. 2012. Nanovaccinology: the next generation of
vaccines meets 21st century materials science and engineering. Vaccine 30:
6609–6611.
42. Roseman, A. M., O. Borschukova, J. A. Berriman, S. A. Wynne, P. Pumpens, and
R. A. Crowther. 2012. Structures of hepatitis B virus cores presenting a model
epitope and their complexes with antibodies. J. Mol. Biol. 423: 63–78.
43. Fehr, T., D. Skrastina, P. Pumpens, and R. M. Zinkernagel. 1998. T cell-
independent type I antibody response against B cell epitopes expressed re-
petitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA 95:
9477–9481.
The Journal of Immunology 13
44. McGuire, T. C., A. J. Musoke, and T. Kurtti. 1979. Functional properties of
bovine IgG1 and IgG2: interaction with complement, macrophages, neutrophils
and skin. Immunology 38: 249–256.
45. Rabbani, H., W. R. Brown, J. E. Butler, and L. Hammarström. 1997. Polymor-
phism of the IGHG3 gene in cattle. Immunogenetics 46: 326–331.
46. Symons, D. B. A., C. A. Clarkson, and D. Beale. 1989. Structure of bovine
immunoglobulin constant region heavy chain gamma 1 and gamma 2 genes.
Mol. Immunol. 26: 841–850.
47. Kacskovics, I., and J. E. Butler. 1996. The heterogeneity of bovine IgG2--VIII.
The complete cDNA sequence of bovine IgG2a (A2) and an IgG1. Mol.
Immunol. 33: 189–195.
48. Saini, S. S., W. Farrugia, N. Muthusamy, P. A. Ramsland, and A. K. Kaushik.
2007. Structural evidence for a new IgG1 antibody sequence allele of cattle.
Scand. J. Immunol. 65: 32–38.
49. Pumpens, P., and E. Grens. 2001. HBV core particles as a carrier for B cell/T cell
epitopes. Intervirology 44: 98–114.
50. Mody, K. T., D. Mahony, A. S. Cavallaro, F. Stahr, S. Z. Qiao, T. J. Mahony, and
N. Mitter. 2014. Freeze-drying of ovalbumin loaded mesoporous silica nano-
particle vaccine formulation increases antigen stability under ambient condi-
tions. Int. J. Pharm. 465: 325–332.
51. Burgdorf, S., and C. Kurts. 2008. Endocytosis mechanisms and the cell biology
of antigen presentation. Curr. Opin. Immunol. 20: 89–95.
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Fig. S1. Characterization of the SV-140-C18 nanoparticles. (A) BJH pore size distribution curve calculated from the 
desorption branch of SV-140-C18; (B) Total pore volume and Brunauer-Emmett-Teller surface area of SV-140-C18 and (C) 





Figure S2. HBcAg specific total IgG antibody levels at day 77 in sera from individual animals inoculated with three doses 
of: HBcAg-p67C (Group 3, N=3), HBcAg-p67C + SV-p67C as two formulations (Group 5, N=3), HBcAg-p67C + SV-p67C 
as one formulation (Group 6, N=3) or HBcAg-p67C + SV-p67C as two formulations under the challenge experiment (Group 






























Table SI. 25-mer linear peptides overlapping by 16 amino acids used in the CD4+/CD8+ proliferation assay and ELISpot; 
and 15-mer linear peptides overlapping in 7 amino acids used in the linear p67C epitope mapping assay.  
25-mer linear p67C peptides used for CD4+ IFNg ELISpot and proliferation assay.
Peptide 1-25 GTGGGSLRGLDLSEEEVKKILDEIV 
Peptide 10-34 LDLSEEEVKKILDEIVKDPSDGELG 
Peptide 19-43 KILDEIVKDPSDGELGLGDLSDPSG 
Peptide 29-53 SDGELGLGDLSDPSGRSSERQPSLG 
Peptide 38-62 LSDPSGRSSERQPSLGPSLVITDGQ 
Peptide 47-71 ERQPSLGPSLVITDGQAGPTIVSPT 
Peptide 56-80 LVITDGQAGPTIVSPTGPTIAAGGE 
15-mer linear p67C peptides used for linear p67C epitope mapping.
Peptide 1-15 GTGGGSLRGLDLSEE 
Peptide 9-23 GLDLSEEEVKKILDE 
Peptide 17-31 VKKILDEIVKDPSDG 
Peptide 25-39 VKDPSDGELGLGDLS 
Peptide 33-47 LGLGDLSDPSGRSSE 
Peptide 41-55 PSGRSSERQPSLGPS 
Peptide 49-63 QPSLGPSLVITDGQA 
Peptide 57-71 VITDGQAGPTIVSPT 
Peptide 65-80 PTIVSPTGPTIAAGG 
